We are proud to share a new study from our members Dr. Athan Baillet and Dr. Denis Mulleman, regarding the search for precision medicine in axial spondyloarthritis (axSpA).
The Study: Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: Results from discovery and validation cohorts.
This study:
-
Confirms the “biomarker gap” in axSpA.
-
Highlights the complexity of treatment response.
-
Underscores the need for ENOTTA’s continued work in finding more robust, multidimensional predictors for tailored treatment.
Congratulations to the research team for these transparent and essential findings!
🔗 Read the full paper on ScienceDirect: [Link]
#ENOTTA #AxSpA #Rheumatology #PrecisionMedicine #ClinicalResearch #Adalimumab
